Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT01984242
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of California, San Francisco, California, United States
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Phase 2
Completed
- Conditions
- Polycythemia VeraPrimary MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
- Interventions
- Biological: RO7490677Drug: Ruxolitinib
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 125
- Registration Number
- NCT01981850
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO5424802
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01981005
An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)
Completed
- Conditions
- Anemia
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 661
- Registration Number
- NCT01974271
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01974258
A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT01967979
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1846
- Registration Number
- NCT01966471
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇯🇵Niigata Cancer Ctr Hospital; Breast Surgery, Niigata, Japan
A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: TrastuzumabDrug: DoxorubicinDrug: CyclophosphamideDrug: PaclitaxelDrug: DocetaxelDrug: CarboplatinDrug: Neo-adjuvant chemotherapy
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 174
- Registration Number
- NCT01964391
- Locations
- 🇩🇿
EHS Oncologie Emir Abdelkader Oran; Service d'Oncologie Médicale, Oran, Algeria
🇩🇿Centre Anti Cancer Beau-fraisier;Service d'oncologie médicale, Algiers, Algeria
🇩🇿CHU Annaba; Service d'Oncologie Médicale, Annaba, Algeria
A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1431
- Registration Number
- NCT01959659
A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1006
- Registration Number
- NCT01959386
- Locations
- 🇩🇪
Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde, Mainz, Germany
© Copyright 2025. All Rights Reserved by MedPath